e-sports league
Florida requires teaching Black history. Some don't trust schools to do it justice
Stock market today: Wall Street mixed at the start of a holiday-shortened weekLjeonida is a reporter and writer with a degree in journalism and communications from the University of Tirana in her native Albania. She has a particular interest in all things digital marketing; she considers herself a copywriter, content producer, SEO specialist, and passionate marketer. Ljeonida is based in Tbilisi, Georgia.
Dodgers announce 5-year contract with LHP Blake Snell
A strong military is essential for maintaining political integrity, economic stability, foreign diplomacy, and its conventional defensive function. These are the core reasons several countries invest heavily in developing their military infrastructure. To boast a strong military equates to having an extensive leverage in influencing global affairs. Before that, however, a powerful military is primarily responsible for protecting a country's territorial integrity and sovereignty. In a world where geopolitical tensions may quickly rise, a strong military deters aggression from foreign threats and protects borders from possible dangers. This is especially important for countries located in areas prone to violence, terrorism, or territorial conflicts. DON’T MISS THIS: Furthermore, a powerful military could assist in driving economic growth in several ways. Military investments frequently result in advances in technology, infrastructure, and research that flow over into civilian industry, just like the invention of the internet which was first a military tool. These innovations by extension also generate jobs, further boosting the strength of an economy. In 2024, a year riddled with conflicts, including the Sudan war, Israel-Hamas conflict and Russia's conflict with Ukraine, militaries from across the globe have been very active. Given their call of duty, the performance and safety of the individuals who make up said armed forces have been dependent on how developed their military architecture is. With that said, here are the 10 countries in the world with the strongest militaries, as perASML Deadline: ASML Investors with Losses in Excess of $100K Have Opportunity to Lead ASML Holding N.V. Securities Fraud LawsuitAfter battling advanced prostate cancer for a decade, Jim Larson said his doctor recommended he try a new treatment. Pluvicto is the brand name for a treatment that kills cancer cells with the radioactive isotope lutetium-177. Pharmaceutical company Novartis offers the treatment at $27,000 per dose — putting the average five-dose treatment at $135,000. "I was all ready to go. We were excited," he said. "But there's no money now to pay for the drug from the government. And without that, it's not going to go anywhere." Earlier this month, the pan-Canadian Pharmaceutical Alliance (pCPA) — which negotiates drug prices for provincial, territorial and federal public health plans — ended talks with Novartis, even though the Canadian Agency for Drugs and Technologies in Health recommends provinces cover Pluvicto treatments. Now, hundreds of eligible patients will need to pay thousands of dollars to access the treatment. Larson is calling for pCPA and Novartis to get back to the table and for the federal government to cover Pluvicto for eligible patients. "If this doesn't happen within the next few months, we're going to start to lose people," he said. "People are going to die." According to the B.C. Cancer Agency, about 3,500 British Columbians are diagnosed with prostate cancer each year, and in 2021 alone, 705 people died from the disease. Pluvicto is one of the few lutetium-177 cancer treatments approved in Canada. The compound is injected intravenously and circulates around a patient's body until it encounters a prostate cancer cell. Then, it attaches itself to the cell before it disintegrates, emitting a beta particle which shreds DNA in the nucleus of the cancer cell — usually killing it. Dr. Philip Cohen, a Metro Vancouver-based nuclear medicine researcher, said the treatment sometimes targets salivary glands and tear ducts, leaving patients with a dry mouth. He said patients often show less severe side effects compared to chemotherapy, which can leave patients feeling nauseous and tired. He said Pluvicto is one of about 20 new compounds reaching Canada's drug approval process that aim to treat cancer in a similar way. Mina Bechai, the CEO and Founder of Initio Medical, a private facility in Burnaby, B.C., where patients can access the treatment, said treatments like the lutetium-177 injection are promising. "They have been very effective, but it all depends on the intervention time," he said. "If you get into it too late, then you won't really be able to help those patients." He said the treatment could help hundreds of cancer survivors, but the high cost prevents many patients from accessing Pluvicto. "Patients have to self-fund their own treatment. That's the sad part," he said. "We've got to do whatever we have to do to make options available." Health Canada first approved Pluvicto in 2022. In B.C., cancer treatments are covered through the B.C. Cancer Agency, which has no compassionate supply of Pluvicto. A spokesperson for B.C. Cancer said after negotiations between the pCPA and Novartis collapsed, British Columbians would have to access the drug through third-party insurance or by paying for the treatment at a private facility. Dominic Tan, acting pCPA CEO, said the alliance ended negotiations over the Pluvicto when it decided Novartis's best offer for the cost of the drug was higher than the pCPA assessed it was worth. "Despite a significant shift from the pCPA to compromise on price, during the many months of negotiation, the price gap for the drug remains too wide," Tan said in an emailed statement. "The pCPA has a responsibility to ensure that the price it negotiates for a drug is consistent with the evidence of its clinical benefit to patients and sustainable for the health system as a whole." Tan said the alliance was disappointed by the result of the negotiation and recognizes the decision may also disappoint the patients, families and caregivers who were awaiting its results. He said the pCPA is willing to head back to negotiations. Meanwhile, a spokesperson for Novartis, said the company was also disappointed by the decision. "We have heard from physicians, physician associations, and patient groups ... who need options that will allow them not only to live longer but also preserve quality of life so they can continue to celebrate important milestones with loved ones," a spokesperson said in an email. Novartis said the average treatment is 4.54 doses. Each dose of Pluvicto must be made to order and requires a highly specialized manufacturing and distribution process to ensure each patient gets the right dose at the right time, which factors into the cost of the treatment, Novartis said. It said it is prepared to pursue all available options to ensure eligible patients can access the treatment. But that's not enough for Larson. He's calling for both sides to get back to the table and come to an agreement. "Nobody wins when you walk away. Everybody loses. Get back to that table, Negotiate until you have a deal."
NEW YORK , Dec. 15, 2024 /PRNewswire/ -- The global heart valve repair and replacement devices market size is estimated to grow by USD 2.58 billion from 2024 to 2028, according to Technavio. The market is estimated to grow at a CAGR of 7.08% during the forecast period. The report provides a comprehensive forecast of key segments below- Segmentation Overview Get a glance at the market contribution of rest of the segments - Download a FREE Sample Report in minutes! 1.1 Fastest growing segment: Heart valve replacement devices are essential medical solutions for individuals with damaged heart valves. These devices are categorized into three types based on the valve material: mechanical, tissue/bioprosthetic, and transcatheter. Mechanical valves, manufactured from synthetic materials like plastic, carbon, or metal, offer durability and longevity, typically lasting about 25 years. They are suitable for patients below 65 years with valve stenosis or regurgitation and a history of atrial fibrillation. However, patients must take anticoagulants for life due to the risk of blood clots. Mechanical valves are ideal for patients with small-sized hearts and are represented by products like Medtronic Open Pivot Mechanical Heart Valves, Edwards INTUITY Elite valve system, and Carbomedics Aortic Family. Tissue/bioprosthetic valves, derived from animal tissues or human donor tissue, provide strength and a ten-year lifespan without anticoagulant consumption. They are recommended for older patients above 65 years. However, they may not be suitable for neonatal and pediatric patients due to their tendency to break down. Some popular bioprosthetic valves include Medtronic's Mosaic and Mosaic Ultra Bioprostheses and Abbott's The EPIC MITRAL STENDED TISSUE VALVE WITH LINX ANTICALCIFICATION technology. Transcatheter heart valves, designed to replace the aortic valve, are minimally invasive, requiring mild sedation and few incisions, with short hospital stays. They are beneficial for patients with aortic valve stenosis, improving their survival rate. Complications associated with transcatheter valves include bleeding, stroke, arrhythmias, kidney disease, infections, and heart attack. Boston Scientific Corporation's LOTUS Edge Aortic Valve System, JenaValve Technology's JenaValve Pericardial TAVR System, and Medtronic's Evolut PRO System are some transcatheter heart valves available in the market. The growth of the heart valve repair and replacement devices market is driven by the increasing prevalence of heart valve diseases, technological advancements, and an aging population. The demand for minimally invasive procedures and the rising awareness of heart valve replacement therapies are also contributing factors. These trends are expected to propel the growth of this market during the forecast period. Analyst Review Heart valves are essential components of the cardiovascular system, allowing the efficient flow of blood between heart chambers and the rest of the body. Damage to heart valves due to congenital defects, acquired conditions such as infections, age-related changes, heart attacks, or calcific degeneration can lead to regurgitation or stenosis, requiring treatment. Heart disease patients may first attempt medicines or lifestyle changes, but when these methods fail, heart valve repair or replacement becomes necessary. Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral Valve Replacement (TMVR) are minimally invasive procedures that have gained popularity due to their lower risk compared to open-heart surgery. The FDA has approved several heart valve repair and replacement devices, leading to numerous acquisitions and innovations in the market. Cardiovascular diseases, including heart valve damage, affect millions worldwide, driving the demand for these devices. However, their high cost and stringent regulatory procedures can limit access to some patients. Diagnostic technologies, such as echocardiography, help identify heart valve issues early, allowing for timely intervention. Heart valve repair and replacement devices are crucial for treating various heart conditions, improving patients' quality of life and longevity. The market for these devices is constantly evolving, with ongoing research and development to address the unique needs of different patient populations. Market Overview Heart valves are essential components of the cardiovascular system, allowing the proper flow of blood through the heart. Damage to heart valves can occur due to congenital defects, age-related changes, infections, heart attacks, calcific degeneration, and other heart diseases. Damaged valves can lead to conditions such as regurgitation or stenosis, which can result in heart failure, stroke, blood clots, and even death. Treatment options include medicines, lifestyle changes, and surgical procedures. Heart valve repair and replacement devices are used to address damaged or diseased valves. These devices include prosthetic valves, such as mechanical and biological valves, as well as transcatheter valves like TAVR and TAVI. The industry has seen significant growth due to the increasing prevalence of cardiovascular diseases and the aging population. However, high costs and regulatory procedures, including FDA approval and stringency, can hinder market growth. Heart valve repair and replacement devices are used for both surgical procedures and minimally invasive percutaneous procedures. Mechanical valves and tissue bioprosthetic valves are common types of surgical heart valves, while transcatheter heart valves and percutaneous heart valves are used for minimally invasive procedures. Industry growth drivers include the increasing number of diagnostic technologies for congenital heart defects and the development of new technologies like TMVR. To understand more about this market- Download a FREE Sample Report in minutes! Key Topics Covered: 1 Executive Summary 2 Market Landscape 3 Market Sizing 4 Historic Market Size 5 Five Forces Analysis 6 Market Segmentation 7 Customer Landscape 8 Geographic Landscape 9 Drivers, Challenges, and Trends 10 Venodr Landscape 11 Vendor Analysis 12 Appendix About Technavio Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contacts Technavio Research Jesse Maida Media & Marketing Executive US: +1 844 364 1100 UK: +44 203 893 3200 Email: media@technavio.com Website: www.technavio.com/ View original content to download multimedia: https://www.prnewswire.com/news-releases/heart-valve-repair-and-replacement-devices-market-size-to-increase-by-usd-2-58-billion-between-2023-to-2028--market-segmentation-by-product-geography-technavio-302331390.html SOURCE Technavio
More Cost-effective, Easier To Build Houses Under NSHP – PM
Storm's Mattson named SPHL Player of the WeekResearchers develop ultra-thin film to power wearables using body heat
- Previous: e-sports example
- Next: e-sports philippines
